drugset / Trial / NCT00199355
A Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease in Patients Taking Levodopa
RandomizedParallel-groupDouble-blindTreatment
Summary
To establish the efficacy of 20 mg/day and 40 mg/day doses of istradefylline for reducing the percentage of OFF time in patients with advanced Parkinson's disease (PD) treated with levodopa.
Timeline
- Start
- 2005-04
- Primary completion
- 2006-03
- Completion
- 2006-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Istradefylline | Small molecule | 20 mg | Oral |
| Subject | Istradefylline | Small molecule | 40 mg | Oral |